1.1 USD
0 (0%)
1.1087 USD
+0.01 (+0.79%)
We assign a fundamental rating of 5 out of 10 to ZYBT. ZYBT was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here. ZYBT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year ZYBT was profitable.
- ZYBT had a positive operating cash flow in the past year.
1.2 Ratios
- The Return On Assets of ZYBT (7.96%) is better than 89.01% of its industry peers.
- ZYBT's Return On Equity of 13.83% is amongst the best of the industry. ZYBT outperforms 87.96% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 12.67%, ZYBT belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for ZYBT is below the industry average of 12.84%.
- The 3 year average ROIC (10.57%) for ZYBT is below the current ROIC(12.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROIC | 12.67% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 12.95%, ZYBT belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
- In the last couple of years the Profit Margin of ZYBT has declined.
- ZYBT's Operating Margin of 16.66% is amongst the best of the industry. ZYBT outperforms 86.39% of its industry peers.
- In the last couple of years the Operating Margin of ZYBT has declined.
- ZYBT's Gross Margin of 54.00% is fine compared to the rest of the industry. ZYBT outperforms 65.97% of its industry peers.
- In the last couple of years the Gross Margin of ZYBT has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% |
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ZYBT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for ZYBT remains at a similar level compared to 1 year ago.
- Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.32 indicates that ZYBT is not a great score, but indicates only limited risk for bankruptcy at the moment.
- ZYBT has a Altman-Z score of 2.32. This is in the better half of the industry: ZYBT outperforms 61.26% of its industry peers.
- ZYBT has a debt to FCF ratio of 6.51. This is a slightly negative value and a sign of low solvency as ZYBT would need 6.51 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 6.51, ZYBT belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
- A Debt/Equity ratio of 0.02 indicates that ZYBT is not too dependend on debt financing.
- ZYBT has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: ZYBT outperforms 54.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Altman-Z | 2.32 |
ROIC/WACC1.6
WACC7.93%
2.3 Liquidity
- A Current Ratio of 1.31 indicates that ZYBT should not have too much problems paying its short term obligations.
- ZYBT has a worse Current ratio (1.31) than 76.44% of its industry peers.
- A Quick Ratio of 0.88 indicates that ZYBT may have some problems paying its short term obligations.
- With a Quick ratio value of 0.88, ZYBT is not doing good in the industry: 80.63% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
- ZYBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.94%, which is quite impressive.
- The Earnings Per Share has been growing by 528.02% on average over the past years. This is a very strong growth
- Looking at the last year, ZYBT shows a very strong growth in Revenue. The Revenue has grown by 43.18%.
- The Revenue has been growing by 854.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.17, the valuation of ZYBT can be described as reasonable.
- Based on the Price/Earnings ratio, ZYBT is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
- ZYBT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- ZYBT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ZYBT is cheaper than 96.34% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, ZYBT is valued cheaply inside the industry as 82.20% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.33 | ||
| EV/EBITDA | 5.73 |
4.3 Compensation for Growth
- ZYBT has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ZYBT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.1
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.33%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap52.13M
Revenue(TTM)303.21M
Net Income(TTM)39.27M
AnalystsN/A
Price TargetN/A
Short Float %0.76%
Short Ratio1.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | N/A | ||
| P/S | 1.2 | ||
| P/FCF | 27.33 | ||
| P/OCF | 8.84 | ||
| P/B | 1.28 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 5.73 |
EPS(TTM)0.12
EY10.91%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY3.66%
OCF(TTM)0.12
OCFY11.31%
SpS0.92
BVpS0.86
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROCE | 14.13% | ||
| ROIC | 12.67% | ||
| ROICexc | 13.42% | ||
| ROICexgc | 14.4% | ||
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% | ||
| FCFM | 4.38% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3Y-33.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 114.94% | ||
| Cap/Sales | 9.16% | ||
| Interest Coverage | 12.67 | ||
| Cash Conversion | 54.97% | ||
| Profit Quality | 33.8% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.32 |
F-Score7
WACC7.93%
ROIC/WACC1.6
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A
ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ
What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT.
What is the valuation status of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
ChartMill assigns a valuation rating of 5 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Fairly Valued.
Can you provide the profitability details for ZHENGYE BIOTECHNOLOGY HOLDIN?
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
The Price/Earnings (PE) ratio for ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 9.17 and the Price/Book (PB) ratio is 1.28.
Can you provide the financial health for ZYBT stock?
The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 4 / 10.